top of page

Receptor Tyrosine Kinase
Mutation Cell Line Panels

Mutations in Receptor Tyrosine Kinases (RTKs)—such as EGFR—drive oncogenic signaling and are critical targets in cancer therapy. To support drug discovery and pathway analysis, Signosis offers BaF3 stable cell lines expressing specific mutant tyrosine kinases, including clinically relevant EGFR variants, validated for signaling studies and inhibitor screening.

​

In addition to EGFR, our cell line panel includes other RTKs mutations such as HER2 and FLT3, as well as the non-receptor Tyrosine Kinase JAK2, expanding utility across multiple oncogenic pathways. We also provide fully sequenced EGFR expression vectors (pMSCV-EGFR-GFP, pCMV-EGFR, and pLenti-MSCV-EGFR-GFP) for gene function analysis and assay development.

Our tools are designed for reliability, reproducibility, and fast integration into your research workflow.

Principle 

Signosis offers a panel of four distinct BaF3 stable cell lines, each engineered to express a specific oncogenic mutant: EGFR, HER2, FLT3, or JAK2. These cell lines were developed using a non-viral, electroporation-based delivery system to introduce expression vectors containing the mutant gene of interest, a GFP reporter, and either hygromycin or puromycin resistance markers into BaF3 cells. As a murine IL-3–dependent pro-B cell line, BaF3 is widely recognized for studying kinase-driven transformation and for evaluating the efficacy of small-molecule inhibitors. Each stable line was selected for high GFP expression and antibiotic resistance, followed by validation through PCR sequencing and confirmation via Western blot using mutation-specific antibodies. These models offer a reliable and well-characterized platform for drug screening, mechanistic studies, and signaling pathway research involving tyrosine kinase mutations.

​

Our expression vectors—pMSCV-EGFR-GFP, pCMV-EGFR, and pLenti-MSCV-EGFR-GFP—are designed for efficient gene function analysis, target discovery, and compound screening. These vectors contain the desired oncogenic mutations in EGFR (or related kinases) and are equipped with a GFP reporter for easy selection and tracking of transfected cells. Each vector is fully sequenced for accuracy and optimized for transgene expression in various cell types. The combination of selectable markers (hygromycin or puromycin resistance) ensures high-efficiency stable cell line generation, supporting robust, reproducible assays in kinase signaling research and drug testing.

pMSCV-EGFR-Hygro-GFP (3).png
pMigR1 (3).png
egfr stable cell line.png

EGFR Mutants

Screenshot 2025-04-25 154317.png

Jak2 Mutants

her2 stable cell line.png

HER2 Mutants

Screenshot 2025-04-25 154317.png

EGFR Vectors

flt3 stable cell line_edited.jpg

FLT3 Mutants

Product Categories

Benefits

RT Research

Our engineered expression cell lines are perfect for studying RTKs and their pathways, or any other relevant molecular or relevant mechanisms.

Double Selection

Single clones are selected with GFP and hygromycin, which can be used to maintain RTK expression.

​Comprehensive Validation

The selected clones have been validated with PCR-sequencing and Western blot analysis.

Functional Analysis

Proliferation tests have been performed on the cell lines with their corresponding inhibitors.

Research Applications

  • Investigating the effects of HER2 mutations on downstream signaling pathways and cellular processes, such as cell proliferation, differentiation, and survival.

  • Identifying novel therapeutic strategies for targeting HER2 and its mutants in cancer by testing the efficacy of various inhibitors or combination therapies.

  • Screening for small molecule compounds or antibodies that selectively target HER2 mutants over wild-type HER2.

  • Developing in vitro and in vivo models to study the mechanisms of resistance to HER2 inhibitors and to test novel combination therapies.

  • Evaluating the potential of HER2 and its mutants as diagnostic and prognostic biomarkers for specific types of cancer.

bottom of page